FDA OKs IncobotulinumtoxinA (Xeomin) First-Line in Blepharospasm


The FDA has approved broadening the indication for incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals) as first-line therapy for blepharospasm in adult patients, the manufacturer has announced, as reported in Medscape.

Benign essential blepharospasm (BEB) causes involuntary and excessive closure of the eyelids. The intramuscular injectable drug was already indicated for patients with BEB who have been previously treated with onabotulinumtoxinA (Botox). However, based on results from a new phase 3 trial, the FDA gave approval today to the supplemental Biologic License Application as a first-line treatment in patients who are botulinum toxin-naïve.

Read the full article.

Recent Content